An unoriginally-named soft basher on the other site seems
An unoriginally-named soft basher on the other site seems to have trouble finding the right tone for his/her new identity.
Just to make it clear: no, CTIX absolutely does not "need to have a partner with[in] the next 2 to 3 months." The company has plenty of money to continue operations for the next year.
It certainly does seem like a half-hearted attempt, so my theory that the big guys have covered and possibly gone long still seems possible.
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Top 5 Most Recently Viewed Articles
Embrace Pet Insurance Partners in Charity and Volunteerism Despite facing economic hurdles, charitable contributions across the nation showed remarkable resilience, highlighting the generosity of individuals and businesses alike. Recent reports reveal that charitable donations in the U.S. hit staggering heights, exceeding $557 billion in the last reporting year. Embrace...
Continue Reading
Exploring Sony's Innovative OLED Technology Sony Semiconductor Solutions Corporation is about to change the landscape of augmented reality (AR) with the introduction of its groundbreaking ECX350F. This 0.44-type Full HD OLED Microdisplay is remarkable for its unique features, including the smallest pixel size in the industry and outstanding brightness. This innovation...
Continue Reading
Bascom Palmer Eye Institute's Unrivaled Recognition in 2025 For an impressive 24th consecutive year, Bascom Palmer Eye Institute has been honored as the premier ophthalmology hospital in the United States. This prestigious recognition, detailed in the 2025 U.S. News & World Report "Best Hospitals" rankings, underscores the institute's unwavering commitment to providing...
Continue Reading
Unusual Options Activity Analysis for Alphabet Inc. Recent trends indicate that prominent financial players are adopting a bearish stance on Alphabet Inc. Our thorough analysis of options history for Alphabet (GOOGL) highlights 20 unusual trades, emphasizing a notable shift in market sentiment. Understanding Trader Sentiment Upon delving into the trade specifics, our...
Continue Reading
uniQure's Recent FDA Feedback The U.S. Food and Drug Administration (FDA) recently provided important insights to uniQure N.V. (NASDAQ: QURE) about its proposed gene therapy for Huntington’s disease. This feedback has led to a noticeable drop in the company’s stock price, reflecting heightened investor concern. Understanding AMT-130 AMT-130 is uniQure’s...
Continue Reading